Jeon Min Ji, Kim Won Gu, Kwon Hyemi, Kim Mijin, Park Suyeon, Oh Hye-Seon, Han Minkyu, Sung Tae-Yon, Chung Ki-Wook, Hong Suck Joon, Kim Tae Yong, Shong Young Kee, Kim Won Bae
Departments of Internal Medicine.
Departments of Clinical Epidemiology and Biostatistics.
Eur J Endocrinol. 2017 Jul;177(1):25-31. doi: 10.1530/EJE-17-0160. Epub 2017 Apr 21.
Active surveillance is an option for patients with papillary thyroid microcarcinoma (PTMC). However, the long-term clinical outcomes after delayed surgery remain unclear. We compared the long-term clinical outcomes of PTMC patients according to the time interval between initial diagnosis and surgery.
In this individual risk factor-matched cohort study, PTMC patients were classified into three groups according to the delay period: ≤6 months, 6-12 months and >12 months. Patients were matched by age, sex, extent of surgery, initial tumor size as measured by ultrasonography (US), and by the presence of extrathyroidal extension, multifocal tumors and central cervical lymph node metastasis. We compared the dynamic risk stratification (DRS) and the development of structural persistent/recurrent disease of patients.
A total of 2863 patients were assigned to three groups. Their mean age was 50 years, 81% were female and 66% underwent lobectomy. The mean tumor size at the initial US was 0.63 cm. There were no significant differences in clinicopathological characteristics between groups after individual risk factor matching. Comparison of the DRS revealed no significant difference according to the delay period ( = 0.07). During the median 4.8 years of follow-up, there were no significant differences in the development of structural recurrent/persistent disease ( = 0.34) and disease-free survival ( = 0.25) between groups.
In PTMC patients, delayed surgery was not associated with higher risk of structural recurrent/persistent disease compared to immediate surgery. These findings support the notion that surgical treatment can be safely delayed in patients with PTMC under close monitoring.
主动监测是甲状腺微小乳头状癌(PTMC)患者的一种选择。然而,延迟手术后的长期临床结果仍不清楚。我们根据初次诊断与手术之间的时间间隔比较了PTMC患者的长期临床结果。
在这项个体风险因素匹配队列研究中,PTMC患者根据延迟期分为三组:≤6个月、6 - 12个月和>12个月。患者按年龄、性别、手术范围、超声(US)测量的初始肿瘤大小以及甲状腺外侵犯、多灶性肿瘤和中央区颈部淋巴结转移情况进行匹配。我们比较了患者的动态风险分层(DRS)和结构性持续性/复发性疾病的发生情况。
共有2863例患者被分为三组。他们的平均年龄为50岁,81%为女性,66%接受了肺叶切除术。初次超声检查时肿瘤的平均大小为0.63厘米。个体风险因素匹配后,组间临床病理特征无显著差异。DRS比较显示根据延迟期无显著差异(P = 0.07)。在中位4.8年的随访期间,组间结构性复发/持续性疾病的发生情况(P = 0.34)和无病生存率(P = 0.25)无显著差异。
在PTMC患者中,与立即手术相比,延迟手术与结构性复发/持续性疾病的较高风险无关。这些发现支持了在密切监测下,PTMC患者的手术治疗可以安全延迟的观点。